Researchers have been battling to find the cure for cancer since we began to understand what cancer really was. A cure is the ultimate goal, but most medical professionals and patients would be ecstatic even hearing about new treatments. Current cancer treatments often come rife with side effects so severe that many choose to forgo them altogether. Stopping the growth of malicious cancer cells is the main goal of treatment, and removing them altogether is even better. The problem is, this kind of treatment almost always causes damage to surrounding healthy cells.
A treatment that changes cancerous cells into healthy, supportive cells sounds ideal. Transforming malignant cells into antibodies that would attack remaining cancer cells sounds too good to be true. Thanks to a groundbreaking study by scientists at The Scripps Research Institute (TSRI), this new, powerful form of cancer therapy could really be on the horizon.
An Accidental Discovery
The laboratory team was working on therapies for certain immune cell or blood factor deficiencies when they noticed some unusual effects of antibodies on marrow cells. They had been searching for antibodies that activate growth-factor receptors on immature bone marrow cells, meaning the antibodies would be able to induce these cells to mature into specific blood cell types.
After successfully identifying a number of antibodies that activated the bone marrow cell-receptors this way, the researchers noticed that some of the antibodies were having unexpected effects on the cells. Some of them were maturing into cells that were radically different from what had been expected, such as neural cells. This got the team thinking, could this method be used to convert cancerous marrow cells (leukemia cells) into non-cancerous cells?
Transformation
In the new study, Richard A. Lerner, institute professor and the Lita Annenberg Hazen professor of Immunochemistry at TSRI and senior investigator, teamed up with colleagues, including first author Kyungmoo Yea, an assistant professor of cellular and molecular biology at TSRI. They decided to test 20 of the recently discovered receptor-activating antibodies on acute myeloid leukemia cells taken from human patients. One of the antibodies ended up having an incredible impact on the leukemia cells.
Most acute myeloid leukemia cells have the thrombopoietin (TPO) receptor, a receptor the winning antibody selectively and potently activated in marrow cells. When the antibody was applied to healthy marrow cells, the cells matured into blood-platelet-producing cells (megakaryocytes). When applied to the acute myeloid leukemia cells, though, the antibody caused them to mature into dendritic cells, which are key support cells in the body’s immune system.
This alone would have been a success — the researchers had effectively transformed cancerous cells into non-cancerous, helpful immune system cells. The team pushed further, though, and found that with longer exposures to the antibodies and other regulated conditions, the dendritic cells matured even more. The final product was a group of cells that very closely resembled natural killer (NK) cells. One of the body’s rapid immune defenses, NK cells are capable of rapidly attacking potentially dangerous pathogens and tumors even if they don’t contain the biomarkers normally identified by other immune cells.
“That antibody could have turned those acute myeloid leukemia cells into a lot of other cell types, but somehow we were lucky enough to get NK cells,” Lerner said in a press release.
‘Fratricide’
These induced NK cells possessed a few unique characteristics, observed by the team through electron microscopy. The cells possessed extending tendrils that had made their way through the outer membranes of closeby leukemia cells — the kind of cells they would still be, had they not been exposed to the antibody. In lab tests, the NK cells betrayed their former brethren at an impressive pace: a “modest” number of NK cells took out about 15 percent of the surrounding leukemic cell population in only 24 hours.
An interesting detail noted by the researchers is the purely fratricidal nature of the NK cells. They attacked only related leukemia cells, while unrelated breast cancer cells did not die off in large numbers when put into contact with the NK cells. The team is still unclear on why exactly the NK cells behave this way, but hypothesize that other, yet-to-be-discovered antibodies could be the key to turning other cancerous cell types into NK cells.
Lerner has named this type of therapy “fratricidins,” and pointed out that they would have several advantages. The antibodies would be clinically useful with little to no modification, and the high specificity of the NK cells would reduce the likelihood of damage to surrounding healthy cells. This would make fratricidins a possible treatment with much more tolerable effects than traditional treatments like chemotherapy.
On top of that, every cancer cell in a population is potentially convertible, so in a successful therapy the cancer-cell population might not just be reduced, but eliminated entirely.
Read more: Cancer Treatment Breakthrough: Researchers Engineer A Way To Make Leukemia Cells Kill Each Other
The Latest on: Cancer Treatment Breakthrough
[google_news title=”” keyword=”Cancer Treatment Breakthrough” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer Treatment Breakthrough
- ‘Kinder’ treatment for childhood brain cancer to be offered by NHS in Englandon April 23, 2024 at 8:01 pm
Dabrafenib with trametinib can halt growth of some tumours for more than three times as long as standard chemotherapy, study shows ...
- Breakthrough rice bran nanoparticles show promise as affordable and targeted anticancer agenton April 23, 2024 at 10:45 am
Plant-derived nanoparticles have demonstrated significant anticancer effects. Researchers recently developed rice bran-derived nanoparticles (rbNPs) that efficiently suppressed cell proliferation and ...
- Ziftomenib Granted Breakthrough Therapy Designation by FDA in R/R AMLon April 23, 2024 at 8:00 am
The investigational drug ziftomenib is currently being evaluated for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia.
- Collaboration and Partnerships in Accelerating Cancer Drug Developmenton April 23, 2024 at 5:53 am
Lorna Rothery spoke to the Cancer Drug Development Forum’s Managing Director, Professor Jaap Verweij and Chairperson of the CDDF Board of Directors, Professor Ruth Plummer, about opportunities and cha ...
- ImmunityBio stock jumps as FDA clears bladder cancer therapyon April 23, 2024 at 2:57 am
Shares of ImmunityBio (IBRX) surged 33% premarket after FDA clearance of its combination therapy for bladder cancer treatment.
- Kura Oncology Gets Breakthrough Designation For Leukemia Therapyon April 22, 2024 at 5:10 am
By Ben Glickman Kura Oncology said Monday it received a breakthrough therapy designation from regulators for ziftomenib, its potential treatment for a ...
- Cancer Breakthrough Found to Boost Immune Cells Without Harmful Side-Effects By Directing Protein Cytokineson April 21, 2024 at 7:00 am
A new way to safely boost immune cells to fight cancer—avoiding harmful side-effects such as hair loss—has been developed.
- Blood cancer breakthrough could lead to 'new era' of treatment, say leading scientistson April 18, 2024 at 9:07 am
A drug breakthrough could usher in a "new era" for how an aggressive form of blood cancer is treated, scientists have said. Described by researchers as a "largely incurable disease", acute myeloid ...
- Drug breakthrough gives hope of new treatment for ‘largely incurable’ blood canceron April 18, 2024 at 9:05 am
A drug breakthrough could usher in a “new era” for how an aggressive form of blood cancer is treated, scientists have said. Described by researchers as a “largely incurable disease”, acute myeloid ...
- Drug breakthrough could usher in 'new era' for blood cancer treatmenton April 17, 2024 at 10:00 pm
Scientists have discovered a promising new drug therapy for an aggressive form of leukaemia, raising hopes of a "new era" for the treatment of blood cancer. Researchers at The Institute of Cancer ...
via Bing News